When a Rush Order Nearly Broke Our Process: A Lesson in Dressing Standards

The Call That Changed My Week

It was a Tuesday afternoon in late February 2024. I was halfway through reviewing a routine batch of ostomy pouch sample runs when my desk phone rang. It was our logistics coordinator.

“We just got a rush order from a major hospital system. They need 50,000 units of hydrocolloid dressing—specifically the Coloplast Comfeel Plus—and they need it in four weeks.”

My stomach dropped. Four weeks for a 50,000-unit order? Normally, we’d require at least eight weeks for that volume. The spec wasn't new to us—Comfeel Plus is a well-known product with a specific thickness profile—but the timeline was brutal.

“What’s the margin?” I asked.

“Paper-thin. The buyer is pushing for a bulk discount. They’ve quoted a unit price that’s 12% below our standard bulk rate for this product line.”

I said, “So we’re supposed to rush production, cut the price, and still hit quality spec? That’s a recipe for a recall.”

She laughed nervously. “Yeah, that’s why I’m calling you.”

(Should mention: this wasn’t a brand-new customer. We’d worked with this hospital system before on smaller orders for continence care catheters. They had a reputation for squeezing vendors, but their volumes were real.)

So I had a decision to make. And I almost made the wrong one.

The Trap I Almost Fell Into

My initial instinct was to push back hard. I wanted to say: “Not at that price, not in that timeline. Full stop.”

But our sales director was eager. He saw a 50,000-unit order as a strategic foothold. “If we nail this,” he argued, “we’re their go-to for wound care. Think of the recurring revenue.”

And you know what? I nearly agreed. It was late in the day. I was tired. The logic seemed sound: secure the account, worry about execution later. I almost told my team, “Let’s make it work and figure out the details.”

Then I remembered a debacle from 2022.

We had accepted a similar rush order—for a different dressing product, an older formula—and we’d cut corners to meet the timeline. We approved a slightly thinner absorbent layer than the standard spec. The reasoning was: “It’s still within the functional range. The patient won’t notice.”

That was wrong. The dressing failed on three patients within the first week. Not dramatically—no serious adverse events—but the absorption was noticeably lower. The hospital complained. We had to re-ship 8,000 units at our cost. The total financial hit was around $22,000, plus the reputational damage with a customer we were trying to grow.

I was not going to repeat that mistake.

Building a Realistic Plan

So I called a late-afternoon huddle with our production scheduler, the procurement lead, and the quality lab supervisor. We put the order’s specifications up on the screen.

For the Coloplast Comfeel Plus hydrocolloid dressing, the critical specs were:

• Hydrocolloid layer thickness: 1.6 mm ± 0.2 mm (this is what gives it the absorption capacity for exudate management)
• Adhesive peel adhesion: Minimum 3.5 N/25 mm per the manufacturer’s published standard for medical-grade hydrocolloids
• Release liner integrity: Must not split during removal in clinical use

I said, “We can’t budge on these. We’re not arguing about approval status; we’re talking about product performance. If these specs slip, the dressing doesn't work as intended.”

To get the timeline down to four weeks, we would need to:

• Source raw materials from a pre-qualified backup supplier (not our primary, but one we’d audited in Q1 2023)
• Run the production line in double shifts for the first two weeks
• Expedite the third-party quality testing at an independent lab—the standard 5-day turnaround had to become 48 hours

The estimated cost premium for all this? About $0.14 per unit. On 50,000 units, that’s $7,000 total.

I presented the numbers to the sales director. “We can meet the timeline, but we need to add $7,000 to the order cost. That’s a 3.5% increase on the quoted price. We tell the customer: here’s the real cost of a compressed schedule. If they want to pay the lower bulk rate, we deliver in eight weeks.”

The Client Pushback

The client’s procurement manager pushed back, of course. They came back with: “Can’t you absorb the cost? You’ll make it up on future orders.”

I replied, “If we absorb this cost, we’re essentially subsidizing an unrealistic timeline. The risk of quality failure—even a minor one—costs far more than $7,000 in reruns, lost trust, and patient safety concerns. We’re not saying no. We’re saying here is what it costs to say yes.”

That conversation was tense. But honestly, after the pushback, I kept second-guessing. What if we lost the whole account because of a $7,000 surcharge? The two weeks until they responded were stressful. I seriously wondered if I’d been too rigid, too focused on the process and not enough on the relationship.

But I held the line. My perspective was: value over price. The lowest unit cost isn’t worth it if the product doesn’t perform, or if we have to cut corners that create risk.

The Outcome

The hospital system agreed to the surcharge. They even admitted—off the record—that they’d had issues with a previous supplier who took a “tight timeline, low price” order and delivered an inconsistent batch. They appreciated the transparency.

We shipped 50,200 units on day 28 (we added a small overrun for safety stock). The independent lab results came back clean: all physical and performance specs within the published tolerances for the Comfeel Plus product range. No complaints from the clinical staff. No returns.

That order led to a follow-up contract for their continence care device line, including a trial of the Coloplast SpeediCath catheters. The relationship didn’t just survive—it deepened.

Looking back, I should have pushed for a tighter spec verification upfront. At the time, I was focused on the price negotiation, but if I could redo that decision, I’d invest the $7,000 in an upfront audit of the backup supplier’s raw material consistency. That would have been an even safer bet. But given what I knew then—that the primary supplier was reliable and the backup had passed audit—my choice was reasonable.

What I Learned

This experience reinforced something I’ve observed over 5+ years in medical device quality management: the cheapest option is rarely the most cost-effective one.

I’ve rejected around 8% of first deliveries in 2024 alone due to specification drift. Most of those rejections came from orders where the timeline was compressed and the cost was squeezed. The correlation is real.

For procurement professionals reading this: if someone promises you a low price and a fast timeline and high quality, they are likely compromising on one of those three. Ask them specifically which spec they are cutting. Then decide if you can live with that risk.

For vendors: don’t be afraid to say “no” to a bad deal. A lost order is a one-time loss. A quality failure can cost you the customer for years.

The bottom line: value over price isn’t a slogan. It’s a calculation. Run the numbers on what a failure costs. You might find that paying a little more upfront is actually the cheapest path.

As of November 2024, the Coloplast Comfeel Plus dressing remains a standard product in our wound care portfolio. The specific thickness (1.6 mm ± 0.2 mm) and peel adhesion (≥ 3.5 N/25 mm) specs are cited from the manufacturer’s published technical data sheet, which we verify quarterly against production batches.